6,963 publications from this institution
Incubation of purified human eosinophil granulocytes (greater than 93%) with the platelet activating factor (PAF), led at concentrations of 1 pM to 10 microM, to a non-cytotoxic and dose-dependent liberation of proteins both from the "small" and the "specific" granules. The mean EC50 for this PAF-induced effect was 1.47 nM (n = 9), with a maximum at 100 nM PAF. The degranulating effect of PAF can be inhibited competitively by the specific PAF-receptor antagonist, WEB 2086 (KB between 12 and 13 nM), and is Ca2(+)-dependent.
The current study reports clinical outcomes at three year follow-up of the LEADERS clinical trial which was the first all-comers trial comparing a new generation biodegradable polymer biolimus drug-eluting stent (BES) with the first generation permanent polymer sirolimus-eluting stent (SES).One thousand seven hundred and seven patients were randomised to unrestricted use of BES (n=857) or SES (n=850) in an all-comers population. Three year follow-up was available in 95% of the patients, 812 treated with BES and 809 treated with SES. At three years, BES remains non-inferior to SES for the primary endpoint of major adverse cardiac events (composite of cardiac death, myocardial infarction (MI), or clinically-indicated target vessel revascularisation (CI-TVR) (BES 15.7% versus SES 19%; HR 0.82 CI 0.65-1.03; p=0.09). The MACE Kaplan Meier event curves increasingly diverge with the difference in events increasing from 1.4% to 2.4% and 3.3% at 1, 2 and 3 years, respectively in favour of BES. The rate of cardiac death was non-significantly lower 4.2% versus 5.2% (HR=0.81 CI 0.52-1.26; p=0.34) and the rate of myocardial infarction was equivalent 7.2% versus 7.1% (HR 1.01 CI 0.70-1.44; p=0.97) for BES versus SES, respectively. Thus BES was non-inferior to SES in all the safety endpoints. Clinically-indicated TVR occurred in 9.4% of BES treated patients versus 11.1% of SES treated patients (HR 0.84 CI 0.62-1.13; p=0.25). Rates of definite stent thrombosis were 2.2% for BES and 2.9% for SES (HR 0.78 CI 0.43-1.43; p=0.43), with the event rate increase of 0.2% from one to three years for BES and 0.9% for SES. For patients presenting with ST-elevation myocardial infarction BES was superior to SES in reducing MACE.The findings of the three year follow-up support the claim that the biodegradable polymer biolimus-eluting stent has equivalent safety and efficacy to permanent polymer sirolimus-eluting stent in an all-comers patient population. Its performance is superior in some subpopulations such as in ST-elevation MI patients and event rates for BES are overall lower than for SES with a trend toward increasing divergence of outcomes over three years.
Background: Optical Coherence Tomography (OCT) is a high resolution imaging technique capable of accurate assessment of polymeric struts, changes in luminal and scaffold dimensions, and quantificat...
Background Whether focal vasospasticity plays a pathogenic role in the progression or regression of coronary atherosclerosis is unknown. To determine whether evidence for such a role exists, we studied long-term changes in coronary luminal measurements in patients with vasospastic angina. Methods and Results Quantitative coronary angiography and repeated ergonovine provocation tests were performed 45±16 months apart in 30 patients. All patients had vasospastic anginal symptoms and coronary spasm on the initial provocation test. Of the 30 patients, 16 had persistent symptoms of vasospastic angina and showed coronary spasm at the same site on the follow-up angiogram (group 1), while the remaining 14 whose vasospastic anginal symptoms disappeared at follow-up demonstrated a negative response to ergonovine on the follow-up tests (group 2). There was no significant difference in patients’ baseline characteristics between the two groups. Long-term changes in minimal (MLD) and mean (MEAN) luminal diameter were measured (in millimeters) after administration of isosorbide dinitrate in 19 spastic and 93 nonspastic segments in group 1 and in 17 previously spastic and 81 nonspastic segments in group 2. Both MLD and MEAN were measured in 210 coronary segments of the 30 patients at baseline and after administration of ergonovine and isosorbide dinitrate by use of a computer-based quantitative coronary angiography system. Stenosis progression and regression of individual lesions were defined as a change in MLD of ≥0.40 mm. In group 1, both the MLD and MEAN of 19 spastic segments were significantly smaller (progression) at follow-up compared with the initial angiogram (MLD, 2.21±0.54 initially versus 1.95±0.65 at follow-up, P <.01; MEAN, 2.80±0.56 initially versus 2.56±0.58 at follow-up, P <.01), whereas the MLD and MEAN of 93 nonspastic segments in group 1 were not significantly different between the initial and follow-up angiograms (MLD, 2.47±0.67 initially versus 2.44±0.69 at follow-up, P =NS; MEAN, 2.96±0.69 initially versus 2.91±0.68 at follow-up, P =NS). In group 2, the MLD of the 17 previously spastic segments significantly improved (regression) at follow-up (MLD, 1.99±0.68 initially versus 2.24±0.54 at follow-up, P <.05); the MLD and MEAN of the 81 nonspastic segments were not significantly different (MLD, 2.36±0.59 initially versus 2.39±0.60 at follow-up, P =NS; MEAN, 2.81±0.58 initially versus 2.81±0.61 at follow-up, P =NS). In group 1, significant stenosis progression of individual lesions was observed more frequently at spastic than nonspastic segments (6 of 19 versus 10 of 93, P <.05), whereas stenosis regression was observed in no spastic and 3 nonspastic segments ( P =NS). In group 2, stenosis progression was observed at 1 previously spastic segment and 4 nonspastic segments ( P =NS), while significant stenosis regression of individual lesions was seen more commonly in previously spastic than nonspastic segments (6 of 17 versus 7 of 81, P <.01). Conclusions These results have demonstrated in patients an association between persistent vasospastic activity and progression of atherosclerosis and an association between cessation of vasospastic activity and regression of atherosclerosis.